Elucid raises $55M for cardiovascular AI

Elucid raised an oversubscribed $55 million Series D, taking total funding to roughly $185 million, according to its financing announcement. The Boston medtech says the money will accelerate commercialization of its AI cardiovascular-imaging platform; its FFR-CT 510(k) submission remains under FDA review while Plaque-IQ is already FDA-cleared. For teams evaluating AI’s role in clinical discovery and care, file the round as commercialization evidence—not clinical proof—until regulatory clearance and deployment outcomes arrive.